Purdue's proposed settlement could be in trouble after it was revealed how much Sacklers profited

It's becoming a little clearer just how much cash the Sackler family raked in from their ownership of Purdue Pharma, the pharmaceutical giant known for making OxyContin and allegedly playing a major role in the opioid epidemic plaguing the United States.
Bankruptcy court filings revealed that Purdue reportedly sent $12 billion or $13 billion in profits to the Sacklers, The Wall Street Journal reports, though it's not clear what years the distribution covered.
The figure is relevant as some states, cities, and tribes are looking to settle lawsuits with Purdue, which has been accused of fueling the opioid crisis through its marketing of OxyContin, while others argue the Sacklers should contribute more than they have agreed to so far. Purdue and the Sacklers deny the allegations about their role in the crisis, but they tentatively struck a deal with some states and local governments, in which the Sacklers would contribute $3 billion toward a potentially $12 billion total settlement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The recent revelations are likely to "bolster resistance" to the settlement, however, the Journal reports. "The Sackler family is trying to take advantage of the fact that they've extracted nearly all the money out of Purdue and pushed the carcass of the company into bankruptcy," North Carolina Attorney General Josh Stein said Friday. "That's unacceptable." Read more at The Wall Street Journal.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
A wine-themed tour of beautiful Uruguay
The Week Recommends Secret paradise in South America boasts beautiful vineyards
By The Week UK Published
-
Romanian democracy: no place for the 'TikTok messiah' Calin Georgescu
Talking Point State is 'fighting back' against poster boy for right-wing conspiracists
By The Week UK Published
-
5 terrifically taxing cartoons about tariffs
Cartoons Artists take on rising prices, dumb ideas, and more
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
Drugmakers paid pharmacy benefit managers to avoid restricting opioid prescriptions
Under the radar The middlemen and gatekeepers of insurance coverage have been pocketing money in exchange for working with Big Pharma
By Theara Coleman, The Week US Published